More importantly, Glo1/MG-H1/PD-L1 axis could represent, through up-stream Glo1 inhibition, a novel attractive target for therapeutic strategies aimed at driving PD-1/PD-L1 blockade and/or helping to overcome hurdles of targeting it with already available PD-1 and/or PD-L1 antibodies, such as atezolizumab in this study, which is an urgent need, especially in the advanced stages of PCa, whose outcome is lethal. Here, CD274 is linked to posterior cortical atrophy.